Glenmark Pharmaceuticals Ltd (GLENMARK):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3318)
◆英語タイトル:Glenmark Pharmaceuticals Ltd (GLENMARK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3318
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:64
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥64,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥96,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Glenmark Pharmaceuticals Ltd (Glenmark) is a pharmaceutical company which focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company’s formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd (GLENMARK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Private Equity 14
Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 14
Partnerships 16
Glenmark Pharma Enters into Agreement with Sam Chun Dang Pharm 16
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 17
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 19
Licensing Agreements 20
Harbour BioMed Enters into Licensing Agreement with Glenmark Pharma 20
Seqirus Enters into Licensing Agreement with Glenmark Specialty 21
Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 22
Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 23
Glenmark Pharma Enters into Licensing Agreement with Helsinn 24
Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 25
Glenmark Pharma Enters into Licensing Agreement with Cyndea Pharma 26
Glenmark Pharma Enters into Licensing Agreement with Advanced Proteome Therapeutics 27
Glenmark Pharma Enters into Licensing Agreement with Evestra for NuvaRing 28
Glenmark Pharma Enters into Licensing Agreement with Particle Sciences 29
Glenmark Generics Enters Into Licensing Agreement With Celon Pharma 30
Equity Offering 31
Glenmark Pharma Raises USD151 Million in Private Placement of Shares 31
Glenmark Pharma Plans to Raise USD300 Million in Private Placement 32
Debt Offering 33
Glenmark Pharma Prices Private Placement of 4.5% Bonds for USD200 Million 33
Glenmark Pharma to Raise up to USD200 Million in Public Offering of Bonds 34
Asset Transactions 35
Glenmark Pharma to Divest its Orthopaedic Business to True North 35
Acquisition 36
Glenmark Pharma Acquires Zorg Labs 36
Glenmark Pharmaceuticals Ltd – Key Competitors 37
Glenmark Pharmaceuticals Ltd – Key Employees 38
Glenmark Pharmaceuticals Ltd – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 42
Financial Announcements 42
May 29, 2018: Glenmark’s consolidated revenue at Rs. 22,798.16 Mn. for Q4 FY 2017 – 18 42
Feb 09, 2018: Glenmark’s consolidated revenue at Rs. 22,036.62 Mn for Q3 FY 2017 – 18 44
Nov 02, 2017: Glenmark’s consolidated revenue increases by 1.46% to Rs. 22,565.90 Mn for Q2 FY 2017–18 45
Jul 27, 2017: Glenmark’s consolidated revenue increases by 19.99% to Rs. 23,630.02 Mn for Q1 FY 2017 – 18 46
May 11, 2017: Glenmark’s consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 – 17 47
Feb 02, 2017: Glenmark Pharmaceuticals Announces Quarter Results Ended December 31, 2016 49
Corporate Communications 50
Nov 02, 2017: Glenmark Appoints Mr. V. S. Mani as Predent & Global Chief Financial Officer 50
Mar 31, 2017: Glenmark: Change in designation of Director 51
Legal and Regulatory 52
Jul 17, 2018: Glenmark Pharmaceuticals to file appeal before NCLAT against CCI penalties 52
Jul 13, 2018: CCI penalises Glenmark Pharma, other entities for unfair business practices 53
Nov 28, 2017: Glenmark Pharmaceuticals: USFDA Audit -Baddi Unit 54
Mar 15, 2017: Glenmark’s Receives US FDA Approval For Ankleshwar plant 55
Feb 21, 2017: Glenmark Pharmaceuticals Provides Update On Ankleshwar Plant In Gujarat 56
Product News 57
12/27/2017: Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets, 1 mg/20 mcg 57
10/23/2017: Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting 2017 58
Apr 23, 2018: Glenmark clinical trial in Jaipur dragged into controversy, CDSCO to probe allegations 59
Product Approvals 60
Apr 25, 2017: Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR 60
Clinical Trials 61
Dec 13, 2017: Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis 61
Mar 29, 2017: Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, in Seasonal Allergic Rhinitis 62
Mar 08, 2017: Glenmark Pharmaceuticals Receives FDA Clearance of IND for GSP 304 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Glenmark Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 14
Glenmark Pharma Enters into Agreement with Sam Chun Dang Pharm 16
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 17
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 19
Harbour BioMed Enters into Licensing Agreement with Glenmark Pharma 20
Seqirus Enters into Licensing Agreement with Glenmark Specialty 21
Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 22
Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 23
Glenmark Pharma Enters into Licensing Agreement with Helsinn 24
Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 25
Glenmark Pharma Enters into Licensing Agreement with Cyndea Pharma 26
Glenmark Pharma Enters into Licensing Agreement with Advanced Proteome Therapeutics 27
Glenmark Pharma Enters into Licensing Agreement with Evestra for NuvaRing 28
Glenmark Pharma Enters into Licensing Agreement with Particle Sciences 29
Glenmark Generics Enters Into Licensing Agreement With Celon Pharma 30
Glenmark Pharma Raises USD151 Million in Private Placement of Shares 31
Glenmark Pharma Plans to Raise USD300 Million in Private Placement 32
Glenmark Pharma Prices Private Placement of 4.5% Bonds for USD200 Million 33
Glenmark Pharma to Raise up to USD200 Million in Public Offering of Bonds 34
Glenmark Pharma to Divest its Orthopaedic Business to True North 35
Glenmark Pharma Acquires Zorg Labs 36
Glenmark Pharmaceuticals Ltd, Key Competitors 37
Glenmark Pharmaceuticals Ltd, Key Employees 38
Glenmark Pharmaceuticals Ltd, Subsidiaries 39

List of Figures
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Glenmark Pharmaceuticals Ltd (GLENMARK):製薬・医療:M&Aディール及び事業提携情報(Glenmark Pharmaceuticals Ltd (GLENMARK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆